• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

信件--作者回复。

Letter--The Authors Respond.

机构信息

1 Pharmacotherapy Outcomes Research Center Department of Pathology University of Utah.

2 Center for Pharmacoepidemiology and Pharmacoeconomic Research Department of Pharmacy Practice, College of Pharmacy University of Illinois at Chicago.

出版信息

J Manag Care Spec Pharm. 2017 May;23(5):599-600. doi: 10.18553/jmcp.2017.23.5.599.

DOI:10.18553/jmcp.2017.23.5.599
PMID:28448774
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10398221/
Abstract

None of the authors of this study are involved in financial or personal relationships with agencies, institutions, or organizations that inappropriately influenced the statistical analysis plan or interpretation of the study results. DiDomenico received an honorarium from Amgen for the preparation of a heart failure drug monograph for Pharmacy Practice News and was a coinvestigator on funded research for the Patient-Centered Outcomes Research Institute. DiDomenico also serves as an advisory board member for a heart failure program at Otsuka America Pharmaceuticals and as an advisory board member at Novartis Pharmaceuticals. Touchette has received unrestricted grant funding from Cardinal Health and Sunovion Pharmaceuticals and has also served as a consultant to, and director of, the American College of Clinical Pharmacy Practice-Based Research Network on a study funded by Pfizer.

摘要

本研究的作者均未与任何机构、单位或组织存在财务或个人关系,这些机构、单位或组织可能会不当影响统计分析计划或研究结果的解释。DiDomenico 因编写 Pharmacy Practice News 的心力衰竭药物专论而收到 Amgen 的酬金,并作为患者为中心的结果研究所资助研究的共同研究者。DiDomenico 还担任 Otsuka America 制药公司心力衰竭项目的顾问委员会成员,以及 Novartis 制药公司的顾问委员会成员。Touchette 从 Cardinal Health 和 Sunovion 制药公司获得了无限制的赠款资金,并且还担任 Pfizer 资助的研究的美国临床药学实践基于研究网络的顾问和主任。

相似文献

1
Letter--The Authors Respond.信件--作者回复。
J Manag Care Spec Pharm. 2017 May;23(5):599-600. doi: 10.18553/jmcp.2017.23.5.599.
2
Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.当代经皮冠状动脉介入治疗急性冠状动脉综合征患者中口服抗血小板药物的应用趋势。
J Manag Care Spec Pharm. 2017 Jan;23(1):57-63. doi: 10.18553/jmcp.2017.23.1.57.
3
Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.急性冠状动脉综合征后口服抗血小板药物 6 个月成本比较。
J Manag Care Spec Pharm. 2018 Aug;24(8):800-812. doi: 10.18553/jmcp.2018.24.8.800.
4
Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.双相抑郁的治疗抵抗和多疗法抵抗标准:共识定义。
Br J Psychiatry. 2019 Jan;214(1):27-35. doi: 10.1192/bjp.2018.257. Epub 2018 Dec 6.
5
Ketamine: stimulating antidepressant treatment?氯胺酮:一种刺激性抗抑郁治疗方法?
BJPsych Open. 2016 May 11;2(3):e5-e9. doi: 10.1192/bjpo.bp.116.002923. eCollection 2016 May.
6
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.LBA02-09:EMBARK 研究:恩扎卢胺或安慰剂联合醋酸亮丙瑞林与恩扎卢胺单药治疗高危生化复发前列腺癌的 3 期随机研究。
J Urol. 2023 Jul;210(1):224-226. doi: 10.1097/JU.0000000000003518. Epub 2023 May 2.
7
CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.继续医学教育/继续护理学教育文章:多发性硬化症的护理框架,第1部分:更新的疾病分类及特定情况下疾病修正治疗的应用
Int J MS Care. 2016 Nov-Dec;18(6):314-323. doi: 10.7224/1537-2073.2016-051.
8
Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.《精神分裂症、分裂情感障碍和首发精神病患者的结构化生活方式教育(STEPWISE):随机对照试验》
Br J Psychiatry. 2019 Feb;214(2):63-73. doi: 10.1192/bjp.2018.167. Epub 2018 Sep 25.
9
Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.患者支持计划参与对免疫介导性疾病的长期持续获益:改善用药行为,降低住院风险。
J Manag Care Spec Pharm. 2021 Aug;27(8):1086-1095. doi: 10.18553/jmcp.2021.20560. Epub 2021 Apr 12.
10
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective.美国成年人注意缺陷多动障碍的经济负担:社会视角。
J Manag Care Spec Pharm. 2022 Feb;28(2):168-179. doi: 10.18553/jmcp.2021.21290. Epub 2021 Nov 22.

本文引用的文献

1
Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.接受经皮冠状动脉介入治疗并使用普拉格雷或替格瑞洛治疗的急性冠状动脉综合征住院患者的医疗资源利用和成本比较。
J Med Econ. 2015;18(11):898-908. doi: 10.3111/13696998.2015.1060979. Epub 2015 Jul 10.
2
Pharmaceutical innovation: impact on expenditure and outcomes and subsequent challenges for pharmaceutical policy, with a special reference to Greece.药物创新:对支出和结果的影响以及药物政策随后面临的挑战,特别提及希腊
Hippokratia. 2014 Apr;18(2):100-6.
3
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.在美国接受经皮冠状动脉介入治疗的急性冠脉综合征患者中,普拉格雷与氯吡格雷的真实世界观察比较。
Curr Med Res Opin. 2014 Nov;30(11):2207-16. doi: 10.1185/03007995.2014.941055. Epub 2014 Jul 18.
4
Pricing and reimbursement of drugs in Sweden.瑞典药品的定价与报销
Eur J Health Econ. 2002;3(1):66-70. doi: 10.1007/s10198-001-0094-1.